GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (FRA:AG8) » Definitions » Peter Lynch Fair Value
中文

Agilent Technologies (FRA:AG8) Peter Lynch Fair Value : €74.62 (As of Apr. 24, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Agilent Technologies Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Agilent Technologies's PEG is 1. Agilent Technologies's 5-Year TTM EBITDA Growth Rate is 15.83. Agilent Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was €4.71. Therefore, the Peter Lynch Fair Value for today is €74.62.

As of today (2024-04-24), Agilent Technologies's share price is €125.30. Agilent Technologies's Peter Lynch fair value is €74.62. Therefore, Agilent Technologies's Price to Peter Lynch Fair Value Ratio for today is 1.68.


The historical rank and industry rank for Agilent Technologies's Peter Lynch Fair Value or its related term are showing as below:

FRA:AG8' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.02   Med: 2.31   Max: 11.7
Current: 1.95


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Agilent Technologies was 11.70. The lowest was 1.02. And the median was 2.31.


FRA:AG8's Price-to-Peter-Lynch-Fair-Value is ranked worse than
66% of 50 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.655 vs FRA:AG8: 1.95

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Agilent Technologies Peter Lynch Fair Value Historical Data

The historical data trend for Agilent Technologies's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies Peter Lynch Fair Value Chart

Agilent Technologies Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.20 24.42 36.26 59.23 68.92

Agilent Technologies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.62 64.97 70.11 68.92 67.94

Competitive Comparison of Agilent Technologies's Peter Lynch Fair Value

For the Diagnostics & Research subindustry, Agilent Technologies's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agilent Technologies's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's Price-to-Peter-Lynch-Fair-Value falls into.



Agilent Technologies Peter Lynch Fair Value Calculation

Agilent Technologies's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 15.83 *4.714
=74.62

Agilent Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.71.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Agilent Technologies  (FRA:AG8) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 15.83 instead of 15 in this case.

Agilent Technologies's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=125.30/74.62
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Agilent Technologies (FRA:AG8) Business Description

Traded in Other Exchanges
Address
5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.

Agilent Technologies (FRA:AG8) Headlines

No Headlines